摘要
目的比较同步放化疗(CCRT)与序贯放化疗(SCRT)治疗中晚期食管鳞癌患者的临床效果。方法选取2017年5月至2019年5月我院收治的86例中晚期食管鳞癌患者,根据治疗方法的不同分为两组各43例。对照组给予SCRT治疗,观察组给予CCRT治疗。治疗后随访8周,比较两组的临床疗效以及血清鳞状细胞癌抗原(SCCA)水平。结果观察组的总缓解率为79.07%,显著高于对照组的53.49%(P<0.05);随访8周结束时,两组的血清SCCA水平均显著低于治疗前,且观察组的血清SCCA水平显著低于对照组(P<0.05)。结论CCRT治疗中晚期食管鳞癌的效果较SCRT更好,可有效降低患者血清SCCA水平,值得临床推广应用。
Objective To compare the clinical effects of concurrent radiochemotherapy(CCRT)and sequential chemoradiotherapy(SCRT)in the treatment of patients with middle-advanced esophageal squamous cell carcinoma.Methods 86 patients with middle-advanced esophageal squamous cell carcinoma admitted to our hospital from May 2017 to May 2019 were selected and divided into two groups according to different treatment methods,with 43 cases in each group.The control group was treated with SCRT,and the observation group was treated with CCRT.All patients were followed up for 8 weeks after treatment,and the clinical efficacy and serum squamous cell carcinoma antigen(SCCA)level were compared between the two groups.Results The total remission rate in the observation group was 79.07%,significantly higher than 53.49%in the control group(P<0.05).At the end of the 8-week follow-up,the serum SCCA levels in both groups were significantly lower than those before treatment,and the serum SCCA level in the observation group was significantly lower than that in the control group(P<0.05).Conclusions CCRT has better effect than SCRT in the treatment of middle-advanced esophageal squamous cell carcinoma,which can effectively reduce the serum SCCA level of patients,and is worthy of clinical promotion and application.
作者
王丽君
冯子龙
牛欢欢
WANG Lijun;FENG Zilong;NIU Huanhuan(Department of Tumor Radiotherapy,Gongyi People's Hospital,Gongyi 451200,China;Department of Pharmacy,Gongyi People's Hospital,Gongyi 451200,China)
出处
《临床医学工程》
2021年第12期1643-1644,共2页
Clinical Medicine & Engineering
关键词
中晚期食管鳞癌
序贯放化疗
同步放化疗
临床疗效
Middle-advanced esophageal squamous cell carcinoma
Sequential chemoradiotherapy
Concurrent radiochemotherapy
Clinical efficacy